William Spreen

9.6k citations

81 papers · 3.8k · 1 hit paper · h-index 31

Impact in

Virology top 0.5%
- HIV Research and Treatment
Infectious Diseases top 0.5%
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions

Papers in

Infectious Diseases 48
- HIV/AIDS drug development and treatment 45
- HIV/AIDS Research and Interventions 18
Virology 31
- HIV Research and Treatment 31

Co-authors: Susan L. Ford (36 shared papers)David A. Margolis (7 shared papers)Arlene R. Hughes (7 shared papers)Stephen C. Piscitelli (6 shared papers)Michael Mosteller (5 shared papers)John C. Pottage (1 shared paper)Eric Lai (4 shared papers)Allen D. Roses (3 shared papers)
Journals: Open Forum Infectious Diseases (14 papers)Antimicrobial Agents and Chemotherapy (8 papers)AIDS (6 papers)HIV Clinical Trials (5 papers)British Journal of Clinical Pharmacology (4 papers)
Partner nations: United States United Kingdom Belgium

In The Last Decade

William Spreen

79 papers receiving 3.6k citations

William Spreen's Hit Papers

align trajectories log scale

Genetic variations in HLA-B region and hypersensitivity reactions to abacavir 2002 · 637 citations

Peers

Countries citing papers authored by William Spreen

Since Specialization

Citations

This map shows the geographic impact of William Spreen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William Spreen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William Spreen more than expected).

Fields of papers citing papers by William Spreen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William Spreen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William Spreen. The network helps show where William Spreen may publish in the future.

Co-authors

The 25 scholars most cited alongside William Spreen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with William Spreen Line = papers co-authored together William Spreen links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 81 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Genetic variations in HLA-B region and hypersensitivity reactions to abacavir The Lancet ·Seth Hetherington, Arlene R. Hughes, Michael Mosteller, Denise Shortino, Katherine L. Baker-Neblett, William Spreen, Eric Lai, Kirstie Davies, Abigail R. Handley, David J. Dow, Mary E. Fling, Michael Stocum, Clive Bowman, Linda M. Thurmond, Allen D. Roses Hit paper breakdown →	2002	637
2	Long-acting injectable antiretrovirals for HIV treatment and prevention Current Opinion in HIV and AIDS ·William Spreen, David A. Margolis, John C. Pottage	2013	210
3	Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations Pharmacogenomics ·Arlene R. Hughes, Michael Mosteller, Aruna T. Bansal, Kirstie Davies, Stephen Haneline, Eric Lai, Keith Nangle, Trevor R. Scott, William Spreen, Liling Warren, Allen D. Roses, on behalf of the CNA and CNA	2004	201
4	Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial The Lancet HIV ·Martin Markowitz, Ian Frank, Robert M. Grant, Kenneth H. Mayer, Richard Elion, Deborah Goldstein, Chester Fisher, Magdalena E. Sobieszczyk, Joel E. Gallant, Hong‐Van Tieu, Winkler G. Weinberg, David A. Margolis, Krischan J Hudson, Britt Stancil, Susan L. Ford, Parul Patel, Elizabeth Gould, Alex R. Rinehart, Kimberly Y. Smith, William Spreen	2017	168
5	Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial The Lancet Infectious Diseases ·David A. Margolis, Cynthia Brinson, Graham Smith, Jerome De Vente, Debbie Hagins, Joseph J. Eron, Sandy Griffith, M H St Clair, Marita Stevens, Peter Williams, Susan L. Ford, Britt Stancil, M Bomar, Krischan J Hudson, Kimberly Y. Smith, William Spreen	2015	164
6	Formulation and pharmacology of long-acting cabotegravir Current Opinion in HIV and AIDS ·Christine Trezza, Susan L. Ford, William Spreen, Rennan Pan, Stephen C. Piscitelli	2015	148
7	Limited CD4+ T-cell renewal in early HIV-1 infection: Effect of highly active antiretroviral therapy Nature Medicine ·Sylvain Fleury, Rob J. de Boer, Gian Paolo Rizzardi, Katja C. Wolthers, Sigrid A. Otto, Craig Welbon, Cecilia Graziosi, Christian Knabenhans, Hugo Soudeyns, Piere-Alexander Bart, Serge Gallant, Jean-Marc Corpataux, M Gillet, Pascal Meylan, P. Schnyder, Jean‐Yves Meuwly, William Spreen, M. P. Glauser, Frank Miedema, Giuseppe Pantaleo	1998	134
8	Long-Acting Integrase Inhibitor Protects Macaques from Intrarectal Simian/Human Immunodeficiency Virus Science ·Chasity D. Andrews, William Spreen, Hiroshi Mohri, Lee Moss, Susan L. Ford, Agegnehu Gettie, Kasi Russell‐Lodrigue, Rudolf P. Bohm, Cecilia Cheng‐Mayer, Zhi Hong, Martin Markowitz, David D. Ho	2014	125
9	GSK1265744 Pharmacokinetics in Plasma and Tissue After Single-Dose Long-Acting Injectable Administration in Healthy Subjects JAIDS Journal of Acquired Immune Deficiency Syndromes ·William Spreen, Susan L. Ford, Shuguang Chen, David Wilfret, David M. Margolis, Elizabeth Gould, Stephen C. Piscitelli	2014	122
10	Campath‐1h, a humanized monoclonal antibody, in refractory rheumatoid arthritis Arthritis & Rheumatism ·Michael E. Weinblatt, Peter J. Maddison, Ken J. Bulpitt, B L Hazleman, Murray B. Urowitz, R D Sturrock, Jonathan S. Coblyn, Agnes L. Maier, William Spreen, Vasant K. Manna, Jeffrey M. Johnston	1995	100
11	Pharmacokinetics, Safety, and Monotherapy Antiviral Activity of GSK1265744, an HIV Integrase Strand Transfer Inhibitor HIV Clinical Trials ·William Spreen, Sherene Min, Susan L. Ford, S. Chen, Yu Lou, M Bomar, Marty St. Clair, Steve Piscitelli, Tamio Fujiwara	2013	97
12	Pharmacokinetics, Safety, and Tolerability With Repeat Doses of GSK1265744 and Rilpivirine (TMC278) Long-Acting Nanosuspensions in Healthy Adults JAIDS Journal of Acquired Immune Deficiency Syndromes ·William Spreen, Peter Williams, David M. Margolis, Susan L. Ford, Herta Crauwels, Yu Lou, Elizabeth Gould, Marita Stevens, Stephen C. Piscitelli	2014	97
13	Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study The Lancet HIV ·Chloe Orkin, Enrique Bernal, Darrell H. S. Tan, Harold Katner, Hans‐Jürgen Stellbrink, Elena Belonosova, Rebecca DeMoor, Sandy Griffith, Shanker Thiagarajah, Rodica Van Solingen‐Ristea, Susan L. Ford, Herta Crauwels, Parul Patel, Amy Cutrell, Kimberly Y. Smith, Kati Vandermeulen, Eileen Birmingham, Marty St. Clair, William Spreen, Ronald D’Amico	2021	90
14	A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge Science Translational Medicine ·Chasity D. Andrews, Yun Lan Yueh, William Spreen, Leslie St. Bernard, Mar Boente-Carrera, Kristina Rodriguez, Agegnehu Gettie, Kasi Russell‐Lodrigue, James Blanchard, Susan L. Ford, Hiroshi Mohri, Cecilia Cheng‐Mayer, Zhi Hong, David D. Ho, Martin Markowitz	2015	72
15	Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase AIDS ·Michael M. Lederman, Ray A. McKinnis, Dennis Kelleher, Amy Cutrell, John W. Mellors, Mike Neisler, Elizabeth Cooney, David W. Haas, Richard Haubrich, James Stanford, James Horton, Alan Landay, William Spreen	2000	72
16	Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults AIDS ·Michael S. Saag, Anders Sönnerborg, Ramón A. Torres, Danny J. Lancaster, Brian Gazzard, Robert T. Schooley, Carmen Romero, Dennis Kelleher, William Spreen, Stephen W. LaFon	1998	72
17	Lack of Pharmacokinetic Interaction between Rilpivirine and Integrase Inhibitors Dolutegravir and GSK1265744 Antimicrobial Agents and Chemotherapy ·Susan L. Ford, Elizabeth Gould, Shuguang Chen, David M. Margolis, William Spreen, Herta Crauwels, Stephen C. Piscitelli	2013	72
18	Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility The Pharmacogenomics Journal ·Arlene R. Hughes, William Spreen, Michael Mosteller, Liling Warren, Eric Lai, Cynthia H. Brothers, Charles Cox, Anita J. Nelsen, Scott Hughes, D. Thorborn, Britt Stancil, Seth Hetherington, Daniel K. Burns, A D Roses	2008	70
19	Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy AIDS ·Pierre‐Alexandre Bart, Gian Paolo Rizzardi, Giuseppe Tambussi, Jean‐Philippe Chave, Aude G. Chapuis, Cecilia Graziosi, Jean-Marc Corpataux, Nermin Halkic, Jean‐Yves Meuwly, Miguel Muñoz, Pascal Meylan, William Spreen, Hugh McDade, Sabine Yerly, Luc Perrin, Adriano Lazzarin, Giuseppe Pantaleo	2000	58
20	The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge Science Translational Medicine ·Jessica Radzio, William Spreen, Yun Lan Yueh, James Mitchell, Leecresia Jenkins, J. Gerardo García‐Lerma, Walid Heneine	2015	57

About William Spreen

William Spreen is a scholar working on Infectious Diseases, Virology, Epidemiology, Hepatology and Pharmacology, having authored 81 papers that have together received 3.8k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (45 papers), HIV Research and Treatment (31 papers), HIV/AIDS Research and Interventions (18 papers), Hepatitis C virus research (10 papers), Drug-Induced Adverse Reactions (7 papers), HIV-related health complications and treatments (5 papers), Pneumocystis jirovecii pneumonia detection and treatment (4 papers) and Autoimmune Bullous Skin Diseases (3 papers). The work is most often cited by research in Virology (1.4k citations), Infectious Diseases (2.0k citations), Pharmacology (546 citations), Emergency Medicine (270 citations) and Pharmacology (242 citations). William Spreen has collaborated with scholars based in United States, United Kingdom and Belgium. Frequent co-authors include Susan L. Ford, David A. Margolis, Arlene R. Hughes, Stephen C. Piscitelli, Michael Mosteller, John C. Pottage, Eric Lai, Allen D. Roses, Elizabeth Gould and Seth Hetherington. Their work appears in journals such as Open Forum Infectious Diseases, Antimicrobial Agents and Chemotherapy, AIDS, HIV Clinical Trials and British Journal of Clinical Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

William Spreen

Impact in

Papers in i

In The Last Decade

William Spreen

William Spreen's Hit Papers

Peers

Countries citing papers authored by William Spreen

Fields of papers citing papers by William Spreen

All Works

About William Spreen

Explore authors with similar magnitude of impact

Papers in